Naka-shi, Ibaraki, Japan Clinical Trials

A listing of Naka-shi, Ibaraki, Japan clinical trials actively recruiting patients volunteers.

Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
I am looking for
added new label for I am looking for
Advanced Filters
Found 48 clinical trials
Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient Investigation

To understand the incidence of ADRs of Calquence 100 mg capsules (acalabrutinib) used in patients with relapsed or refractory chronic lymphocytic leukaemia (including small lymphocytic lymphoma) in a real-world post-marketing setting

Research Site
 (8.3 away) Contact site
  • 18 Mar, 2022
  • +11 other locations
VAXZEVRIA Japan Post-Marketing Surveillance (PMS) for the Subjects With Underlying Disease at High-risk for Worsening COVID-19

To provide more information on safety profile of VAXZEVRIA in Japanese subjects, specific drug use result study in subjects with underling disease at higher risk of worsening COVID-19 is planned as an additional pharmacovigilance plan. The present study aims to collect information on adverse drug reactions or COVID-19 infection after …

Research Site
 (8.3 away) Contact site
  • 11 May, 2022
  • +5 other locations
A Study to Identify Participants With Urothelial Cancer and Fibroblast Growth Factor Receptor Gene Aberrations

The purpose of this non-interventional study is to identify participants with urothelial cancer (UC) and selected fibroblast growth factor receptor (FGFR) aberrations through molecular testing of their archival tumor tissue.

transitional cell carcinoma
growth factor
Hitachinaka General Hospital
 (5.1 away) Contact site
  • 24 May, 2022
  • +157 other locations
Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ Tablets

Rheumatoid Arthritis (RA) is a chronic inflammatory disease causing pain, stiffness, swelling and loss of joint function. RA can reduce the ability to perform everyday tasks. The purpose of this study is to observe the incidence of serious infections, regardless of their relationship to RINVOQ, in Japanese daily practice. RINVOQ …

Hitachinaka General Hospital /ID# 225326
 (5.1 away) Contact site
  • 24 May, 2022
  • +778 other locations
Special Drug Use-results Survey to Evaluate Safety and Efficacy of Cosentyx in Pediatric Patients With PsV, PsA, or GPP

This is a multicenter, centrally registered observational study without a control group. This observational study is a specified drug use-results survey conducted under GPSP to collect information on safety and efficacy during the observation period (52 weeks after the start of treatment with this drug) in pediatric patients with psoriasis …

psoriasis vulgaris
Novartis Investigative Site
 (8.0 away) Contact site
  • 19 Apr, 2022
  • +16 other locations
Long Term Special Drug Use-results Surveillance for Mayzent in SPMS Patients

This study is a single cohort, central registration system, all-case, open-label, multicenter observational study in patients using Mayzent for the indication of secondary progressive multiple sclerosis.

secondary progressive multiple sclerosis
Novartis Investigative Site
 (5.1 away) Contact site
  • 05 May, 2022
  • +166 other locations
A Study to Evaluate Adverse Events and Change in Disease State of Oral Upadacitinib in Adolescent Participants Ages 12 to <18 Years Old Diagnosed With Atopic Dermatitis (AD)

Atopic dermatitis (AD; also known as atopic eczema) is an inflammatory skin disease. The safety and effectiveness of upadacitinib for AD has been well-documented in previous studies, however, these studies included a limited number of adolescent patients in Japan. Therefore, the purpose of this observational study is to evaluate safety …

topical steroids
inflammatory dermatosis
topical agents
Mito Kyodo General Hospital /ID# 243745
 (6.0 away) Contact site
  • 13 May, 2022
  • +27 other locations
Special Drug-use Surveillance for Kesimpta for s.c. Injection 20 mg Pen

This study is an uncontrolled, central registration system, open-label, multicenter observational study in patients using Kesimpta for the labeled indication.

Novartis Investigative Site
 (5.8 away) Contact site
  • 25 May, 2022
  • +81 other locations